Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Perrigo Company plc    PRGO   IE00BGH1M568

PERRIGO COMPANY PLC

(PRGO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Perrigo : Buys Prevacid U.S. OTC Rights From GlaxoSmithKline

share with twitter share with LinkedIn share with facebook
09/05/2019 | 09:10am EDT

By Chris Wack

Perrigo Company said Thursday it is buying the branded over-the-counter rights to Prevacid from GlaxoSmithKline.

Perrigo said under the terms of the agreement, it will have the exclusive rights to market, sell and distribute Prevacid 24HR in the U.S. OTC market.

Financial terms of the agreement weren't disclosed.

Prevacid 24HR treats frequent heartburn occurring two or more days a week.

Write to Chris Wack at chris.wack@wsj.com

Stocks mentioned in the article
ChangeLast1st jan.
GLAXOSMITHKLINE PLC 0.01% 1573.2 Delayed Quote.-11.58%
PERRIGO COMPANY PLC -5.70% 51.98 Delayed Quote.6.70%
share with twitter share with LinkedIn share with facebook
Latest news on PERRIGO COMPANY PLC
12:09pPERRIGO : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULT..
AQ
07:43aPERRIGO CO PLC : Results of Operations and Financial Condition, Financial Statem..
AQ
07:18aPERRIGO : 2Q Earnings Snapshot
AQ
06/24PERRIGO CO PLC : Change in Directors or Principal Officers (form 8-K)
AQ
06/24PERRIGO : Furthers Its Consumer-Focused Transformation by Divesting Its U.K. Gen..
AQ
06/19PERRIGO CO PLC : Entry into a Material Definitive Agreement, Creation of a Direc..
AQ
06/19PERRIGO : Partners With Kazmira LLC to Enter CBD Market through a Two-Phased, Sc..
AQ
05/28PERRIGO COMPANY PLC : Ex-dividend day for
FA
05/06PERRIGO COMPANY PLC : Report
CO
05/06PERRIGO COMPANY PLC : Proxy Statments
CO
More news
Financials (USD)
Sales 2020 5 179 M - -
Net income 2020 268 M - -
Net Debt 2020 2 700 M - -
P/E ratio 2020 24,5x
Yield 2020 1,75%
Capitalization 7 514 M 7 514 M -
EV / Sales 2020 1,97x
EV / Sales 2021 1,86x
Nbr of Employees 11 200
Free-Float 99,4%
Chart PERRIGO COMPANY PLC
Duration : Period :
Perrigo Company plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PERRIGO COMPANY PLC
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 12
Average target price 56,20 $
Last Close Price 51,98 $
Spread / Highest target 23,1%
Spread / Average Target 8,12%
Spread / Lowest Target -23,0%
EPS Revisions
Managers
NameTitle
Murray S. Kessler President, Chief Executive Officer & Director
Rolf Allan Classon Chairman
Raymond P. Silcock Chief Financial & Accounting Officer
Thomas Farrington Chief Information Officer & Executive VP
Grainne Quinn Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
PERRIGO COMPANY PLC6.70%7 514
JOHNSON & JOHNSON0.93%387 604
ROCHE HOLDING AG2.26%299 665
PFIZER, INC.-2.02%213 250
MERCK & CO., INC.-10.20%206 143
NOVARTIS AG-16.12%185 541